Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201420 | 0.96 | KMT2A (0.47) | KMT2ASMPD3NPY5RNOTUMSCN9A | |
| SCHEMBL2200867 | 0.96 | KMT2A (0.47) | KMT2ASMPD3NPY5RNOTUMSCN9A | |
| SCHEMBL2201606 | 0.96 | KMT2A (0.47) | KMT2ASMPD3NPY5RNOTUMSCN9A | |
| SCHEMBL2202314 | 0.89 | KMT2A (0.47) | KMT2ANPY5RNOTUMSCN9ASCN10A | |
| SCHEMBL2202211 | 0.89 | KMT2A (0.47) | KMT2ANPY5RNOTUMSCN9ASCN10A | |
| SCHEMBL2202124 | 0.88 | SMPD3 (0.41) | KMT2ASMPD3NPY5RNOTUMSCN9A | |
| SCHEMBL2201293 | 0.88 | SMPD3 (0.41) | KMT2ASMPD3NPY5RNOTUMSCN9A | |
| SCHEMBL2201296 | 0.88 | SMPD3 (0.41) | KMT2ASMPD3NPY5RNOTUMSCN9A | |
| SCHEMBL12429652 | 0.86 | KMT2A (0.44) | KMT2ASMPD3NPY5RNOTUMSCN9A | |
| SCHEMBL2201084 | 0.84 | KMT2A (0.49) | KMT2ANPY5RNOTUMSCN9ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029963-A1 | PYRAZOL DERIVATIVES | CCR1, CCR3, CCRL2 | KMT2A 4057/4885SMPD3 3106/4885NPY5R 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.